OncoMatch/Clinical Trials/NCT06715826
Target-specific immunoPET Imaging of Breast Cancer
Is NCT06715826 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments including [18F]F-RESCA-RT4 and [18F]F-RESCA-RB14 for breast cancer.
Treatment: [18F]F-RESCA-RT4 · [18F]F-RESCA-RB14 — The aim of this study is to establish and optimize the Trop2/HER2-targeted PET/CT imaging method, and its physiological and pathological distribution characteristics, on the basis of which the diagnostic efficacy of the above imaging agents in breast cancer will be evaluated.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Breast Carcinoma
Disease stage
Metastatic disease required
Breast Cancer Metastatic
Demographics
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06715826 currently recruiting?
Yes, this trial is currently recruiting patients.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages